Liquidia (LQDA) FCF Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -672.00 |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 1,020.00 |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 1,090.00 |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 2,747.00 |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 1,003.00 |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 56,699.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56,699.00 |
| Mar 31, 2026 | 116,643.00 |
| Dec 31, 2025 | 86,770.00 |
| Sep 30, 2025 | 68,778.00 |
| Jun 30, 2025 | 12,555.00 |
| Mar 31, 2025 | -26,838.00 |
| Dec 31, 2024 | -46,457.00 |
| Sep 30, 2024 | -36,158.00 |
| Jun 30, 2024 | -52,882.00 |
| Mar 31, 2024 | -66,675.00 |
| Dec 31, 2023 | -26,223.00 |
| Sep 30, 2023 | -14,184.00 |
| Jun 30, 2023 | 9,408.00 |
| Mar 31, 2023 | 8,364.00 |
| Dec 31, 2022 | 14,070.00 |
| Sep 30, 2022 | -198.00 |
| Jun 30, 2022 | 3,026.00 |
| Mar 31, 2022 | 12,330.00 |
| Dec 31, 2021 | 167,429.00 |